Gene and Cell Therapies Targeting CNS Disorders Market is expected to grow at a 30.5% CAGR during the forecast period of 2025-2034.
Key Industry Insights & Findings from the Report:
Cell and gene therapy-based therapies have the potential to be an effective and disease-modifying treatment for diseases that would otherwise be incurable with traditional medicines. Due to the rising demand for cell-based immunotherapies and gene therapy products to treat conditions such as prostate and blood cancers. Another factor driving market expansion is the increasing use of cell therapy products in hospitalized patients to treat burns, venous leg ulcers, diabetic foot ulcers, traumas, and pressure ulcers. Also, due to excellent safety and efficacy profiles for treating a wide range of disorders, specific cell and gene therapy treatments are getting regulatory approvals faster than other medicines. As the approval process becomes more simplified, companies are launching these items on the market more quickly.
Additionally, rising R&D efforts, government initiatives to utilize sustainable components in manufacturing, and investments by major players are likely to generate lucrative revenue opportunities for players in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market over the forecast period. During the projection period, the recurrence of the current pandemic is likely to have a positive impact on the worldwide Gene and Cell Therapies Targeting CNS Disorders market. Due to the increased intervention of life-threatening diseases such as heart disease, AIDS, cystic fibrosis, and age-related problems, the industry is likely to expand its borders. The high cost of gene treatments, on the other hand, is expected to hinder market expansion to some extent throughout the forecast period.
The Gene and Cell Therapies Targeting CNS Disorders market is segmented based on product and Indication. Based on the product, the market is segmented as gene therapy and cell therapy. By Indication, the market is segmented into amyotrophic Lateral Sclerosis, Multiple sclerosis, Spinal Cord Injure, Alzheimer, Parkinson Disease, Huntington, and Other Indications. Based on Indications, the Huntington segment is accounted as a major contributor in the Gene and Cell Therapies Targeting CNS Disorders market. The Huntington category is expected to hold a major share in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market in 2021. As a result of the approval of an increasing number of gene therapies for cancer therapy and the segment's growth is being fueled by greater emphasis on research to develop effective cancer treatments, as well as rising cancer research investments.
The market is expected to develop in the coming years due to the availability of numerous gene therapy products that can be used to treat cancer and a huge patient population. Cell therapy segment witness growth at a rapid rate. The cell therapy segment is projected to grow at a rapid rate in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market. The cell therapy segment is growing due to the introduction of innovative and breakthrough products as well as the widespread use of CAR T-cell-based therapies. Cell therapy is the most rapidly developing technology in cancer treatment, with the potential to replace multiple present treatments., especially in countries such as the US, Germany, UK, China, and India.
The North America gene and cell therapy market is expected to show the highest market share in terms of revenue soon. In both regional and global markets, the United States is the major contributor. This is due to the introduction of novel cell and gene therapy products. Due to the elevated prevalence of chronic diseases in countries like China and Japan, APAC is expected to become a key market during the forecast period. Developers of cell and gene therapies are receiving support from both the public and private sectors. In terms of R&D activity and financing to develop and commercialize cell and gene therapy products, North America and Europe are at the forefront. The regulatory approval process, particularly in the United States, is evolving and becoming favourable for vendors for developing cell and gene therapy products.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 30.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Indications |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Novartis, Brainstorm Cell Therapeutics, Helminth, Core set, Q therapeutics, Helminth, Rapa Therapeutics, Brainstorm Cell Therapeutics, Neuroblast, Osteocyte Orchard Therapeutics plc. (UK), SIBIONO (China), Shanghai Sunway Biotech Co., Ltd. (China), bluebird bio, Inc. (US), Human Stem Cells Institute (Russia), Ange’s, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals, Inc. (Ireland), Ackee Therapeutics (US), and Donavan Technologies (US) |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene and Cell Therapies Targeting CNS Disorders Market Snapshot
Chapter 4. Global Gene and Cell Therapies Targeting CNS Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Gene Therapy
5.2.2. Cell Therapy
Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Amyotrophic Lateral Sclerosis
6.2.2. Multiple sclerosis
6.2.3. Spinal Cord Injury
6.2.4. Alzehimer
6.2.5. Parkinson Disease
6.2.6. Huntington
6.2.7. Othe Indications
Chapter 7. Gene and Cell Therapies Targeting CNS Disorders Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
7.1.3. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.2.3. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.3.3. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.4.2. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.4.3. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.5.2. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.5.3. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. BrainStorm Cell Therapeutics
8.2.3. Helixmith
8.2.4. Corestem
8.2.5. Q therapeutics
8.2.6. Helixmith
8.2.7. Rapa Therapeutics
8.2.8. BrainStorm Cell Therapeutics
8.2.9. Neuroplast
8.2.10. StemCyte
8.2.11. Ferrer Internacional
8.2.12. Neuralstem
8.2.13. Ferrer Internacional
8.2.14. Stemedica Cell Technologies
8.2.15. Libella Gene Therapeutics
8.2.16. Sangamo Therapeutics
8.2.17. Hoffmann-La Roche
8.2.18. Longeveron
8.2.19. Sio Gene Therapies
8.2.20. Prevail Therapeutics (Eli Lilly and Company)
8.2.21. NeuroGeneration
8.2.22. Brain Neurotherapy Bio (AskBio)
8.2.23. UniQure Biopharma
8.2.24. Neurogene Inc.
8.2.25. Passage Bio
8.2.26. AXOVANT SCIENCES GMBH
8.2.27. MeiraGTx Limited
8.2.28. Asklepios BioPharmaceutical (AskBio)
8.2.29. Biogen
8.2.30. Sarepta Therapeutics
8.2.31. REGENXBIO Inc.
8.2.32. Lysogene
8.2.33. Voyager Therapeutics
8.2.34. PTC Therapeutics
8.2.35. Other Prominent Players
By Products
By Indications
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
